Saddiq Bader Habiballah, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphopenia | 1 | 2022 | 282 | 0.760 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2022 | 234 | 0.750 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2020 | 672 | 0.280 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2021 | 613 | 0.280 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 5152 | 0.260 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 2 | 2021 | 299 | 0.230 |
Why?
|
| Neonatal Screening | 1 | 2022 | 557 | 0.160 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2021 | 626 | 0.160 |
Why?
|
| Immunomodulation | 1 | 2020 | 535 | 0.150 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 1787 | 0.130 |
Why?
|
| Biological Products | 1 | 2021 | 842 | 0.120 |
Why?
|
| Hydronephrosis | 1 | 2013 | 275 | 0.110 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 1850 | 0.100 |
Why?
|
| Immunologic Factors | 1 | 2020 | 1575 | 0.100 |
Why?
|
| Urinary Tract | 1 | 2013 | 295 | 0.100 |
Why?
|
| Antiviral Agents | 1 | 2021 | 2797 | 0.090 |
Why?
|
| T-Lymphocytes | 2 | 2022 | 10376 | 0.080 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2013 | 1600 | 0.070 |
Why?
|
| Infant, Newborn | 2 | 2022 | 24742 | 0.060 |
Why?
|
| Asthma | 1 | 2021 | 5940 | 0.060 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3160 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3278 | 0.050 |
Why?
|
| Interleukin-6 | 2 | 2021 | 3216 | 0.050 |
Why?
|
| Antibody-Dependent Enhancement | 1 | 2020 | 17 | 0.050 |
Why?
|
| Azetidines | 1 | 2021 | 146 | 0.050 |
Why?
|
| Pandemics | 1 | 2020 | 7292 | 0.050 |
Why?
|
| Macrophage Activation Syndrome | 1 | 2020 | 101 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 17432 | 0.050 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 445 | 0.040 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2020 | 365 | 0.040 |
Why?
|
| Purines | 1 | 2021 | 600 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2020 | 633 | 0.040 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 553 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2020 | 702 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2020 | 1211 | 0.030 |
Why?
|
| Saudi Arabia | 1 | 2013 | 194 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2020 | 1578 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2021 | 1932 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 1490 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2021 | 1976 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2021 | 10542 | 0.020 |
Why?
|
| Humans | 6 | 2022 | 717237 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 2865 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2021 | 41221 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2020 | 2951 | 0.020 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2013 | 741 | 0.020 |
Why?
|
| Gene Expression | 1 | 2020 | 8013 | 0.020 |
Why?
|
| Cytokines | 1 | 2021 | 7223 | 0.020 |
Why?
|
| Infant | 2 | 2020 | 34574 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 9597 | 0.020 |
Why?
|
| Child | 2 | 2021 | 74387 | 0.010 |
Why?
|
| Prognosis | 1 | 2021 | 29226 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 14903 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 15271 | 0.010 |
Why?
|
| Male | 3 | 2021 | 351380 | 0.010 |
Why?
|
| Female | 3 | 2021 | 377909 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2021 | 62348 | 0.010 |
Why?
|
| Risk Factors | 1 | 2021 | 70864 | 0.010 |
Why?
|
| Incidence | 1 | 2013 | 20653 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2020 | 72614 | 0.010 |
Why?
|
| Adolescent | 1 | 2020 | 85139 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 39302 | 0.010 |
Why?
|
| Time Factors | 1 | 2013 | 41095 | 0.010 |
Why?
|